Dear Colleagues: I would like to share a very important milestone for Division of Pharmacometrics (DPM) at FDA (https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/division-pharmacometrics). Today, DPM is the largest division (N=31) across all the review divisions within Office of Clinical Pharmacology at US FDA (OCP, https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/office-clinical-pharmacology)!
When I joined FDA in 2003, there were only four pharmacometric reviewers scattered across three clinical pharmacology divisions (DCP1/2/3, back then there were only 3 divisions within Office of Clinical Pharmacology and Biopharmaceutics, OCPB, which later changed to OCP). Over the years, the function of pharmacometrics was first centralized under Dr. Larry Lesko's (former OCPB and OCP Office Director) leadership and Dr. Bob Powell served as the first head of Pharmacometrics followed by Dr. Joga Gobburru and Dr. Vikram Sinha. We grew from a Team to Pharmacometrics Staff and eventually Division of Pharmacometrics. The number of review teams also increased from 2 to the current 7 (5 pharmacometric teams, 1 PBPK team and 1 cross-discipline QT team). We are proud of our achievements and, more importantly, appreciate the accumulative efforts and hard work of our current and former colleagues both within and outside FDA, including you all. We will build upon the success and move the field of pharmacometrics to the next level in the years to come. Thanks Yaning Wang, Ph.D. Director Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research Food and Drug Administration Phone: 301-796-1624 Email: yaning.w...@fda.hhs.gov<mailto:yaning.w...@fda.hhs.gov> Disclaimer: The contents of this message are mine personally and do not necessarily reflect any position of the Government or the Food and Drug Administration.
